Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenues of $1.05 billion, up 9% year-over-year, driven by strong growth in Xywav, Epidiolex, and Zepzelca, while Xyrem declined due to generic competition.

• Net income for Q3 2024 was $215.1 million, a 46% increase compared to Q3 2023, with adjusted net income up 23% to $417 million and adjusted EPS up 37% to $6.61.

• Affirmed 2024 total revenue guidance at $4.0–$4.1 billion, with neuroscience guidance unchanged and oncology guidance slightly lowered due to temporary Rylaze impact.

• Advanced zanidatamab development with FDA Priority Review for 2L BTC (PDUFA date Nov 29, 2024) and positive Phase 3 Zepzelca data, with sNDA planned for 1H25.

• Continued investment in pipeline and commercial execution, with capital deployment supporting long-term growth in neuroscience and oncology.

Financial highlights

• Q3 2024 total revenues reached $1.055 billion, up from $972 million in Q3 2023; product sales, net, rose 5% to $989.7 million; royalties and contract revenues more than doubled to $65.3 million.

• Non-GAAP adjusted net income was $416.9 million ($6.61 per diluted share), up from $340.1 million ($4.84) year-over-year.

• Gross margin was 88.7% GAAP and 92.6% non-GAAP in Q3 2024.

• Cash, cash equivalents, and investments totaled $2.6 billion at quarter-end; net cash from operations for the nine months was $997.3 million.

• Operating margin for Q3 2024 was 49% non-GAAP and 24.7% GAAP; net income margin was 20.4%.

Outlook and guidance

• 2024 total revenue guidance affirmed at $4.0–$4.1 billion; neuroscience $2.825–$2.925 billion; oncology $1.08–$1.13 billion.

• Adjusted net income guidance of $1.275–$1.35 billion; non-GAAP EPS guidance raised to $19.50–$20.60.

• Lowered R&D expense guidance due to pipeline prioritization; R&D and SG&A expenses expected to increase in 2024.

• Oncology guidance slightly lowered due to temporary Rylaze protocol impact, expected to normalize by early 2025.

• Expect zanidatamab FDA decision by November 29, 2024, and plan to submit sNDA for Zepzelca in 1H25.